ArtivionvsMerck & Company

AORT and MRK stock compared: price, dividend, valuation and results, from SEC filings.

AORT

Artivion, Inc.

$18.47

Value $884M

-3.30%
AORT's page

MRK

Merck & Company, Inc.

$144.46

Value $357B

-2.23%
MRK's page

Artivion (AORT) has a market value of $884M and Merck & Company (MRK) $357B. Over the last year, with dividends, AORT moved -59.6% and MRK +60.0%. Dividend yield: AORT none, MRK 2.35%.

At a glance

The main figures of both. A bar only shows which number is larger, not which is better.

  • Market value

    AORT$884M

    MRK$357B

    MRK is 404 times AORT

  • Revenue, 12 months

    AORT$482M

    MRK$67.4B

    MRK is 140 times AORT

  • Net income, 12 months

    AORT-$18M

    MRK$2.5B

  • Operating margin

    AORT2.3%

    MRK–

  • ROIC

    AORT1.2%

    MRK3.9%

    2.7 points apart

  • P/E

    AORT–

    MRK145.6

  • Dividend yield

    AORT0.0%

    MRK2.4%

    2.4 points apart

  • 5-year return

    AORT-7.0%

    MRK+101.1%

    108.1 points apart

A fainter bar means a negative number. The 5-year return includes dividends.

The price over time

Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.

AORT-7.0%

MRK+101.1%

10020020222023202420252026
Returns by period
PeriodAORTWith dividendsMRKWith dividends
1 year since November 14, 2025-59.6%Price -59.6%+60.0%Price +55.5%
3 years since November 16, 2023+31.1%+9.4% a yearPrice +31.1%+55.2%+15.8% a yearPrice +41.6%
5 years since November 15, 2021-7.0%-1.5% a yearPrice -7.0%+101.1%+15.0% a yearPrice +72.6%
10 years since November 16, 2016-4.1%-0.4% a yearPrice -4.1%+228.0%+12.6% a yearPrice +141.7%

Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.

Every figure

As on each company's page. A description, not a recommendation: no one figure says which is better.

AORTArtivionMRKMerck & Company

Valuation

AORTMRK
Valuation
Price$18.47$144.46
Market value$884M$357B
Enterprise value (EV)$1.2B$401B
P/E–145.6
P/E, 5-year median–14.8
P/B2.08.0
EV/EBIT108.984.3
Free cash flow yield–4.1%

Results and growth

AORTMRK
Results and growth
Revenue, 12 months$482M$67.4B
Net income, 12 months-$18M$2.5B
Free cash flow, 12 months-$44M$14.7B
Earnings per share, 12 months-$0.36$0.98
Revenue growth, year on year13.6%1.3%
Revenue growth a year, past+11.8%over 5 years+9.4%over 5 years
EPS growth a year, past–+21.2%over 5 years

Margins and returns on capital

AORTMRK
Margins and returns on capital
Gross margin63.3%71.8%
Operating margin2.3%–
Net margin-3.7%3.6%
ROIC1.2%3.9%
ROE-4.0%5.2%

Balance sheet

AORTMRK
Balance sheet
Cash$48M$9.7B
Total debt$407M$53.8B
Net debt / EBITDA9.55.7
Interest cover0.4×2.4×

Dividends and buybacks

AORTMRK
Dividends and buybacks
Dividend yield–2.4%
Dividend per share, 12 months–$3.40
Dividend growth a year, past–+5.8%over 5 years
Buyback yield–1.4%
Shareholder yield–3.8%

Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.

Questions: AORT or MRK

Didn't find what you were looking for?

Ask us
Which is bigger, Artivion or Merck & Company?

By market value, Merck & Company ($357B) is about 403.8 times Artivion ($884M), at today's prices.

How did AORT and MRK stock do over the last 10 years?

Since November 16, 2016, AORT's price moved -4.1% and MRK's +141.7%. With dividends: AORT -4.1% (-0.4% a year), MRK +228.0% (+12.6% a year). Past returns do not predict future ones.

Which pays the higher dividend, AORT or MRK?

The dividend yield at today's price is none for Artivion and 2.35% for Merck & Company. Over the last twelve months they paid – and $3.40 per share.

Which has the higher profit margins, Artivion or Merck & Company?

Over the last twelve months, the net margin was -3.7% for Artivion and 3.6% for Merck & Company, and the operating margin 2.3% and –. Revenue was $482M and $67.4B.

Which is the better investment, Artivion or Merck & Company?

The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.

Other comparisons

With each of the two, and with the largest in its sector.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

Descriptive data from SEC filings and market prices.